Centene Corporation is the largest provider of government-sponsored healthcare programs in the United States, reporting $153.9 billion in total revenue for FY2024 and serving approximately 26 million members across all 50 states through Medicaid, Medicare Advantage, and ACA Marketplace plans. Founded in 1984 and headquartered in St. Louis, Missouri, the company employs approximately 73,000 people globally and trades on the NYSE under ticker CNC with a market capitalization of approximately $40 billion. The company is led by CEO Sarah London, who succeeded long-time leader Michael Neidorff in 2022.
Centene Corporation: Key Facts
- Founded: 1984 in St. Louis, Missouri
- Headquarters: St. Louis, Missouri, United States
- CEO: Sarah London (since January 2022)
- FY2024 Revenue: $153.9 billion
- FY2024 Net Income: $2.2 billion
- FY2024 Free Cash Flow: $4.0 billion
- Employees: Approximately 73,000
- Market Cap: Approximately $40 billion
- Members Served: Approximately 26 million
- Primary Business: Government-sponsored managed care
How Does Centene Corporation Make Money?
Centene generates 100% of its $153.9 billion in FY2024 revenue from three primary mechanisms. First, capitated Medicaid premiums: state governments pay Centene a fixed per-member-per-month (PMPM) amount to administer healthcare benefits for low-income enrollees. The Medicaid segment accounts for approximately 71% of revenue ($110 billion). Second, Medicare Advantage premiums: CMS pays Centene risk-adjusted monthly premiums for each senior or disabled member enrolled in a Medicare Part C plan; this segment generated over $25 billion in FY2024. Third, ACA Marketplace premiums: Centene collects premiums from individuals purchasing health insurance on the Affordable Care Act exchanges, generating over $15 billion in FY2024. A fourth, rapidly growing revenue source is the Specialty segment via Magellan Health, generating approximately $3.9 billion through behavioral health, radiology benefit management, and pharmacy benefit management services.
The financial mechanics are defined by the Medical Loss Ratio (MLR): federal law mandates that insurers spend at least 80-85% of premiums on medical care. This structural constraint forces Centene to operate with a 2.3% operating margin, but generates massive absolute dollar profits—$3.5 billion in FY2024 operating income—through the sheer scale of its $153.9 billion premium base.
Who Founded Centene Corporation?
Centene Corporation was founded in 1984 in Wisconsin by Herbert S. Moskowitz and others as a third-party administrator for Medicaid managed care, initially focusing on administering benefits for low-income individuals and families. The company's transformative era began in 1996 when Michael Neidorff joined as CEO and orchestrated an aggressive series of acquisitions that transformed Centene from a regional operator into a national powerhouse. During Neidorff's 25-year tenure as CEO, the company completed its largest acquisitions: Health Net ($6.8 billion, 2016), Fidelis Care ($3.75 billion, 2018), WellCare Health Plans ($17.3 billion, 2020), and Magellan Health ($15.3 billion, 2022). Neidorff retired in 2021 and was succeeded by Sarah London in January 2022.
What Is Centene's Competitive Advantage?
Centene's single unreplicable moat is its proprietary national provider network and risk adjustment infrastructure, built through four decades of continuous investment in government-sponsored healthcare administration. The physical infrastructure required to administer healthcare benefits for 26 million members is not a simple network of call centers; it requires a highly complex, CMS-compliant, data-driven care management system capable of handling everything from routine preventive care to complex behavioral health interventions. This architecture is protected by regulatory approvals, state contracts, and proprietary analytics software that create barriers to entry competitors cannot close in under a decade. Centene's negative working capital cycle—collecting premiums before paying medical claims—generates billions in operational cash flow, funding aggressive acquisitions and share repurchases even at thin margins.
Centene Revenue History
Centene's revenue growth reflects its aggressive acquisition strategy and the expansion of government healthcare programs. The company reported $120 billion in FY2022, $137 billion in FY2023, and $153.9 billion in FY2024—a 12% year-over-year increase driven by membership growth across Medicaid, Medicare Advantage, and ACA Marketplace segments. The Medicaid segment remains the largest revenue driver at approximately 71% of the total, while Medicare Advantage has grown to approximately 16% as the company positions for higher-margin senior care growth. ACA Marketplace contributes approximately 10%.
Centene Business Model Explained
Centene operates a managed care model that is structurally constrained by federal Medical Loss Ratio requirements. For every dollar of premium revenue, at least 80-85 cents must be spent on medical care and quality improvement, leaving only 15-20 cents to cover administrative costs and profit. The company's operating margin of approximately 2.3% is characteristic of the managed care industry and reflects this intense regulatory pressure. However, the negative working capital cycle—where premiums are collected monthly but medical claims are paid weeks to months later—generates $4.0 billion in free cash flow on a $153.9 billion revenue base, providing the financial flexibility to fund strategic acquisitions and return capital to shareholders through buybacks.
Key Acquisitions That Shaped Centene
Four acquisitions fundamentally transformed Centene's scale and competitive positioning. The 2016 acquisition of Health Net ($6.8 billion) established Centene's West Coast presence in California and expanded its Medicare Advantage footprint. The 2018 acquisition of Fidelis Care ($3.75 billion) secured dominance in New York's Medicaid market, one of the nation's largest. The 2020 acquisition of WellCare Health Plans ($17.3 billion) was the defining move, doubling Centene's Medicare Advantage membership and establishing national presence in all 50 states. The 2022 acquisition of Magellan Health ($15.3 billion) marked the company's pivot toward integrated behavioral health, adding a network of mental health, radiology benefit management, and pharmacy benefit management services that command higher margins than traditional Medicaid premiums.
Centene's Legal and Regulatory Challenges
Centene faces three significant legal and regulatory challenges. First, the Department of Justice is investigating allegations that the company submitted false claims to Medicare by upcoding patient diagnoses to receive higher premium payments—a practice known as risk adjustment fraud. This investigation, disclosed as a material contingency in SEC filings, could result in a multi-billion dollar liability. Second, Centene agreed to a $6.4 billion opioid settlement payable through 2038 at approximately $400 million annually, significantly constraining capital allocation flexibility. Third, the Medicaid redetermination process—where states resumed eligibility reviews following the end of the COVID-19 continuous coverage provision—has driven the disenrollment of millions of members, compressing Medicaid segment revenue and profitability.
What Is Centene's Growth Strategy?
Centene's growth strategy rests on three specific initiatives. First, the national rollout of Magellan Health's integrated behavioral health solutions to capture a share of the $50 billion annual behavioral health market and establish a new standard of care for Medicaid and Medicare members. Second, the expansion of the Medicare Advantage portfolio to capture the highest-margin segments of the senior healthcare market, targeting over $40 billion in Medicare Advantage sales by 2032. Third, systematic deleveraging to reduce total long-term debt from $12.5 billion to under $10 billion by 2028, utilizing free cash flow to retire high-yield bonds while servicing the opioid settlement. The company targets a 5-7% constant currency sales CAGR through 2030.
What Are Centene's Biggest Risks?
The biggest risk is the convergence of regulatory scrutiny, structural margin compression, and the financial burden of the $6.4 billion opioid settlement. The DOJ risk adjustment investigation threatens multi-billion dollar liability and could force a fundamental change in Centene's coding practices, reducing premium revenue. Rising medical utilization rates post-pandemic have driven the medical loss ratio higher, compressing the 2.3% operating margin toward breakeven in some quarters. The Medicaid redetermination process has driven the disenrollment of millions of members, reducing the premium volume that generates the free cash flow funding Centene's strategy. The opioid settlement at $400 million per year through 2038 severely limits capital allocation flexibility. Any combination of these factors—DOJ settlement, MLR deterioration, and Medicaid membership decline—could trigger a cascading financial crisis.
Bottom Line
Centene Corporation is simultaneously the dominant infrastructure provider for America's healthcare safety net and one of the most regulatory- and litigation-exposed companies in the managed care industry. The $153.9 billion in FY2024 revenue, generated by administering healthcare for 26 million low-income and senior members, represents the physical manifestation of the US government's reliance on private insurers to manage public health programs. The 2022 acquisition of Magellan Health was the company's most consequential strategic bet, transforming it from a pure-play Medicaid administrator into an integrated behavioral health platform with the potential to escape the structural margin compression of its government contract business. Whether Centene can successfully execute this transformation while simultaneously navigating the DOJ investigation, absorbing the opioid settlement, and managing Medicaid membership churn will determine whether the $40 billion market capitalization represents a significant discount to intrinsic value or an accurate assessment of a highly regulated, low-margin enterprise.
